Compare VRAX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | DRCT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 1.9M |
| IPO Year | 2021 | 2021 |
| Metric | VRAX | DRCT |
|---|---|---|
| Price | $2.63 | $1.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 481.2K | 10.0K |
| Earning Date | 06-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $34,694,000.00 |
| Revenue This Year | $217,274.83 | $5.42 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.04 |
| 52 Week High | $13.19 | $7.21 |
| Indicator | VRAX | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 25.78 |
| Support Level | $2.55 | $1.52 |
| Resistance Level | $3.10 | $1.96 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 4.55 | 7.14 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.